Clinical trial NCT00757159: Study on Regenerative Treatment of Intra-bony Defects
Official title: Randomised, Clinical Controlled Study on Treatment of Intra-bony Defects With Enamel Matrix Protein (Emdogain®) vs. Nanocrystalline Hydroxyapatite (Ostim®)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Periodontal Disease
Periodontal Attachment Loss
Keywords: Periodontal disease
Hydroxyapatite
Enamel matrix protein
Regeneration
Human
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2008-09-23
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this investigation is to determine whether a synthetic hydroxyapatite is as effective as an enamel matrix protein for periodontal regeneration in patients who have intra-bony periodontal defects.

Detailed description: Regeneration of periodontal tissues that have been diminished by periodontal disease is the main goal of periodontal therapy. While conventional surgical therapy only offers limited potential towards recovering tooth-supporting tissues, more recently developed techniques lead to a greater and more predictable regeneration of the periodontal structures. Among these techniques, application of enamel matrix proteins or bone grafts can promote periodontal regeneration.

The study is a prospective, controlled, mono-center, randomized, clinical trial, that is open to the operator, blinded to the examiner. It will be conducted in a parallel group design. Participants who have at least 1 intra-bony periodontal defect will receive regenerative surgery at baseline with the randomly selected devices. A newly developed synthetically manufactured bone grafting material made of hydroxyapatite (Ostim) will be the product under investigation. An enamel matrix protein derivative (Emdogain) will act as control device. Both materials will be applied in intra-bony defects during periodontal flap surgery. Follow-ups will take place at 7 and 14 days post surgery, and at 3, 6, 9, and 12 months.

The primary aim is to compare the effectiveness of the test product with the control in the treatment of 1- and 2-wall intrabony periodontal defects on the amount of bone fill 12 months after surgery. Secondary parameters will be the clinical attachment level gain and reduction of probing pocket depth at 6 and 12 months.

Eligibility criteria: Inclusion Criteria:

* Males and females aged between 18 and 70 years.
* Presence of at least one 1- or 2-wall intrabony periodontal defect.
* Defect width at least 2 mm.
* Defect depth at least 4 mm.
* Defect located at a single rooted tooth or at the approximal site of a multi-rooted tooth if the tooth is not affected by a furcation involvement.
* Written informed consent.
* Subject must be judged healthy by the investigator at the time of surgery.
* Subjects must have had a plaque index \< 0.8 at the end of the initial periodontal therapy.

Exclusion Criteria:

* Medical conditions required prolonged use of steroids.
* Standard blood tests performed by the medical practitioner showing leukocyte dysfunction and deficiencies.
* History of haemophilia, bleeding disorders, or cumarin therapy.
* History of neoplastic disease requiring the use of chemotherapy.
* History of radiation therapy of the head and neck.
* History of renal failure or chronic renal diseases.
* Chronic liver diseases.
* Severe or uncontrolled metabolic bone disorders.
* Uncontrolled endocrine disorders (including diabetes).
* Current pregnancy at the time of recruitment.
* Physical handicaps that would interfere with the ability to perform adequate oral hygiene.
* Use of any investigational drug or device within the 90 day period prior to surgery on study day 0.
* Alcoholism or chronical drug abuse.
* Immuno-compromised patients (including HIV).
* Smokers (occasional smoking is allowed).
* Conditions or circumstances , in the opinion of the investigator, that could represent a general contra-indication for surgical procedures or would prevent completion of study participation or interfere with analysis of study results, such as a history of non-compliance, or unreliability.
* Local inflammation.
* Mucosal diseases (e.g. erosive lichen planus).
* History of local radiation therapy.
* Presence of oral lesions (e.g. ulceration, malignancy).
* Inadequate oral hygiene or patient who is unmotivated for home care.
* Teeth with untreated endodontic or cariologic problems.
* Defects that during surgery show deviation from the inclusion criteria.

Primary outcomes:
measure: Amount of bone fill after surgery
timeFrame: 12 months
Secondary outcomes:
measure: Clinical attachment level gain and reduction of probing pocket depth
timeFrame: 6 and 12 months
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Dresden University of Technology, Dental School, Department of Conservative Dentistry
Study officials:
affiliation: Technische Universität Dresden
name: Thomas Hoffmann, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Al Machot E, Hoffmann T, Lorenz K, Khalili I, Noack B. Clinical outcomes after treatment of periodontal intrabony defects with nanocrystalline hydroxyapatite (Ostim) or enamel matrix derivatives (Emdogain): a randomized controlled clinical trial. Biomed Res Int. 2014;2014:786353. doi: 10.1155/2014/786353. Epub 2014 Feb 9.